The P2RY4 antibody targets the P2Y4 receptor, a G protein-coupled receptor (GPCR) belonging to the P2Y family of purinergic receptors. These receptors bind extracellular nucleotides like uridine triphosphate (UTP) and are involved in diverse physiological processes, including ion channel regulation, inflammation, and neurotransmission. P2RY4 is primarily activated by UTP and, in some species, by ATP, depending on its structural variations. It is expressed in tissues such as the gastrointestinal tract, immune cells, and the central nervous system, where it modulates cellular responses through Gq/11-mediated signaling pathways, leading to phospholipase C activation and intracellular calcium mobilization.
Antibodies against P2RY4 are critical tools for studying its expression, localization, and function in both normal and pathological contexts. They enable researchers to investigate receptor distribution via immunohistochemistry, quantify protein levels using techniques like Western blotting, and block receptor activity in functional assays. P2RY4 has been implicated in diseases such as inflammatory disorders, cancer, and neurological conditions, making its antibody valuable for exploring its role in pathogenesis or therapeutic targeting. However, species-specific differences in P2RY4 ligand sensitivity (e.g., human vs. rodent) require careful validation of antibody specificity. Recent studies also highlight its potential in regulating epithelial secretion and immune responses, underscoring the relevance of P2RY4 antibodies in translational research.